5-Year Survival Improved With Early Use of Ruxolitinib in Myelofibrosis

An analysis of 5-year data from two large clinical trials provides conclusive support that treatment with ruxolitinib improves long-term survival compared with other treatment options for patients with myelofibrosis. Perhaps even more importantly, the data suggest that treatment with ruxolitinib should be implemented much earlier in the course of a patient’s disease because it provides a survival advantage over starting treatment with ruxolitinib at a later point in the disease.

 Cancer Connect

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.